Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO

NCT07152392 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Associated Ophthalmopathies

Interventions

DRUG: IBI311
OTHER: Follew-up

Sponsor

Shanghai Changzheng Hospital